Epilepsy Pipeline Update:
Sponsored by the Epilepsy Therapy Project a 501 (c) (3) non-profit organization dedicated to finding new treatments for epilepsy
Continuing the tradition of the Antiepileptic Drug Conferences (AED I - IX) but with a focus on
drug development strategies, investing and business development opportunities
CNS is a major therapeutic area where great scientific and clinical advances are being made, generating tremendous opportunity for investors and industry. Epilepsy in particular provides the ultimate portal into CNS drug development due to well-characterized mechanisms, therapeutic approaches and functional models supporting drug discovery. Epilepsy also provides a flexible platform for pursuing a number of CNS indications as a first in-human pathway for demonstrating safety, PK/PD and therapeutic proof of concept.
The Epilepsy Pipeline update will provide participants with insights from scientific, academic, clinical, industry and investment thought leaders, first hand, on making the right choices in epilepsy drug development and broader CNS areas and markets. Anti-epilepsy drug development provides a well-understood and structured opportunity to explore novel CNS therapeutic programs. Participants will learn how entry into CNS through the advancement of candidate molecules can yield both much-needed new epilepsy therapeutics, and be leveraged to achieve so much more. You will learn all you need to know about this field in one full day, with opportunities to network with the experts during this conference.
Get on the mailing list for details by contacting email@example.com
An in-depth, one-day forum where emerging CNS companies and scientific entrepreneurs will present their strategies, product candidates and development programs to potential venture capital, private equity, pharma and biotech investors and partners. Hand-selected by the Scientific and Business Advisory Boards of Epilepsy Therapy Project, presenters will cover the most innovative and intriguing therapeutic targets and candidates in development today for epilepsy with potential to be exploited for broader CNS development.
Attendees will hear insights from scientific, academic, clinical and industry leaders on making informed decisions about investment in epilepsy therapy development and broader CNS areas and markets. Major CNS scientific and clinical advances are creating tremendous opportunity for investors and industry, which demand a close understanding of risk profile and product lifecycle management for these novel therapies. As we have seen historically and continue to see, epilepsy in particular provides the ultimate portal into CNS therapeutic development with well-characterized mechanisms, therapeutic approaches, functional models and defined clinical endpoints. We hope you will join us for this rich one-day opportunity.
Business development, company management, venture and crossover investors focused on financing and partnering opportunities in the epilepsy and CNS space and those interested in emerging drugs in the pipeline.
|7:30 a.m.||Registration & Continental Breakfast, Lobby Level Foyer|
|8:00 a.m.||Welcome & Overview - Co-Chairs: Warren Lammert (Granite Point Capital) & Garry Menzel PhD (Credit Suisse)|
|8:10 a.m.||Keynote Lecture: Shared Molecular Mechanisms: Epilepsy to Other CNS Indications, John Krystal, MD (Yale University)|
|9:00 - 11:30 a.m.||How do these treatments work? Moderator: Jacqueline French, MD (New York University)
Approaches to finding better drugs for patients with epilepsy include searching for new mechanisms, improving drugs with known mechanisms, and developing therapies using devices. The benefits and risks of each of these opportunities will be explored in this session.
|9:05 -9:25 a.m.||Screening and Models: How they speed development, Steven White, PhD (University of Utah, NINDS-ADD Program)|
|9:25 - 9:45 a.m.||Evolutionary Treatments: New approaches to known mechanisms, Jacqueline French, MD (New York University)|
|9:45 - 10:00 a.m.||Break|
|10:00 - 10:20 a.m.||Revolutionary Treatments: New CNS drug targets and breakthrough epilepsy treatment strategies, Michael Rogawski, MD, PhD (University of California, Davis)|
|10:20 - 10:40 a.m.||New Technology Platforms: New formulations, delivery systems, C. James Cloyd, PhD (University of Minnesota)|
|10:40 - 11:00 a.m.||Devices: Brain stimulators, implants, Steven Schachter, MD (Harvard University)|
|11:00 - 11:30 a.m.||Questions from Investors, Moderators: Jacqueline French, MD (New York University), Ned Scheetz (Aphelion Capital)|
|11:30 a.m.||Box Lunch ( Foyer)|
Where will the next epilepsy blockbuster come from? This session will provide highlights of a series of novel emerging devices and drugs. Presenters will briefly answer a series of questions describing their concepts and plans, followed by questions from the audience. Moderator: Joyce Cramer (ETP President)
“5 Slides in 5 Minutes”
|2:45 p.m.||Epilepsy & CNS Market Dynamics: The Value Proposition in Epilepsy and Beyond; Panelists: David Barrow (L.E.K. Consulting)(moderator), Heath Lukatch, PhD (Novo Ventures), Anand Mehra, MD (Sofinnova), Roger Quy, PhD (Technology Partners), Gregory Went, PhD (Adamas)|
|3:30 p.m.||Shared Mechanisms, Broader Opportunities, Development Paths in Epilepsy, Pain, Anxiety: Lessons Learned and Applied in the Clinical Development of Epilepsy and CNS Treatments; Panelists: Frank Fischer (Neuropace)(moderator), Rich Denness (UCB), Brian Klein, PhD (J&J), John Krystal MD (Yale), Manuel Lopez-Figueroa PhD (Bay City Capital)|
|4:15 p.m.||Regulatory Issues: How to Manage the FDA Process. Panelists: Elizabeth Garofalo, MD (formerly Pfizer) (moderator), Henry Mansbach, MD (Valeant), Kenneth Sommerville, MD (UCB), Reese Terry (Cyberonics), Mark Versavel, MD, Sepracor|
|5:00 p.m.||An Opinionated Examination of the Epilepsy Pipeline; Panelists: Orrin Devinsky (NYU)(moderator), Steven Collins, MD, PhD (Ovation), Jacqueline French, MD (NYU), Ka Lum (Jazz), Roger Porter, MD (formerly Wyeth), Daniel O’Connell (NeuroVentures), Nancy Santilli (Endo)|
|5:45 p.m.||Business Model for Partnering With Investors, Industry and Entrepreneurs, Joyce Cramer (ETP President)|
|5:55 p.m.||Epilepsy & CNS Therapeutic Development – Everyone Can Benefit, Garry Menzel PhD (Credit Suisse), Warren Lammert (Granite Point Capital), Co-Chairs|
|6:00-8:00 p.m.||Networking Reception for all Registrants
Sydney Lounge, Hotel Monaco Lower Level
Conference Steering Committee
Registration Fees - Limited Seating
The Epilepsy Pipeline Conference will be held at the Hotel Monaco San Francisco. Hotel rooms are available for a special rate of $229.00 per night. Please make your reservations by contacting the Hotel Monaco directly at: 1-800.546.7866 or at 415.351.7632.
To obtain the special rate for the conference, please let the Hotel Monaco know that you will be attending the Epilepsy Pipeline Conference.